Literature DB >> 6791942

Effect of angiotensin-II blockade on systemic and hepatic haemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites.

V Arroyo, J Bosch, M Mauri, F Ribera, F Navarro-López, J Rodés.   

Abstract

We have studied the effect of angiotensin-II blockade with saralasin on the cardiovascular and hepatic hemodynamics and on the renin-angiotensin-aldosterone system in fourteen patients with cirrhosis and ascites. Control measurements showed that most of the patients had a low mean arterial pressure, high plasma volume, normal or high cardiac index, low peripheral resistance and high plasma renin activity and aldosterone concentration. The wedged hepatic venous pressure was increased in each patient and the estimated hepatic blood flow was normal in most of them. Overall, saralasin induced a significant reduction of the mean arterial pressure, cardiac index and peripheral resistance. The decrease of the peripheral resistance was greater than that of the cardiac index. Six of the patients developed a marked reduction of the mean arterial pressure with low doses of saralasin (1--2.5 microgram/kg/min), and they had significantly higher plasma renin activity and lower mean arterial pressure than the remaining eight patients who showed a slight or no hypotensive response in spite of infusing saralasin up to a dose of 10 micrograms/kg/min. Overall, the decrease of the mean arterial pressure correlated directly with the baseline values of plasma renin activity. Angiotensin-II blockade induced a significant reduction of the wedged hepatic venous pressure. The hepatic blood flow did not show any significant change. The decrease of the wedged hepatic venous pressure was directly related to the reduction of the mean arterial pressure and also to the control plasma renin activity. Our study indicates that in most patients with cirrhosis, ascites and high plasma renin activity, arterial pressure is maintained by the effect of endogenous angiotensin II on the peripheral vasculature, and we suggest that a pre-existing arterial hypotension secondary to an arteriolar vasodilatation is the cause of renin release in these patients. Our results also show that angiotensin-II blockade is accompanied by a reduction of the post-sinusoidal hepatic vascular resistance.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6791942     DOI: 10.1111/j.1365-2362.1981.tb01844.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  19 in total

Review 1.  Angiotensin converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease.

Authors:  J Vlachogiannakos; A K Tang; D Patch; A K Burroughs
Journal:  Gut       Date:  2001-08       Impact factor: 23.059

2.  Effects of orthotopic liver transplantation on vasoactive systems and renal function in patients with advanced liver cirrhosis.

Authors:  Concepcíon Cassinello; Enrique Moreno; Adolfo Gozalo; Blanca Ortuño; Beatriz Cuenca; José Antonio Solís-Herruzo
Journal:  Dig Dis Sci       Date:  2003-01       Impact factor: 3.199

3.  Portal pressure, renal function and hormonal profile after acute and chronic captopril treatment in cirrhosis.

Authors:  F R Ibarra; C Afione; D Garzon; M Barontini; J C Santos; E Arrizurieta
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 4.  Pathophysiology of portal hypertension and its clinical links.

Authors:  Yeon Seok Seo; Vijay H Shah
Journal:  J Clin Exp Hepatol       Date:  2011-11-09

Review 5.  The endocrinology and pathophysiology of alcoholic cirrhosis and functional renal failure--a review.

Authors:  E S Domurat; A N Elias
Journal:  J Natl Med Assoc       Date:  1992-02       Impact factor: 1.798

6.  The hepatorenal syndrome.

Authors:  M Pinzani; R D Zipser
Journal:  Intensive Care Med       Date:  1987       Impact factor: 17.440

7.  Treatment of ascites in patients with cirrhosis of the liver.

Authors:  V Arroyo; P Ginés; J Rodés
Journal:  Intensive Care Med       Date:  1987       Impact factor: 17.440

8.  [Effect of captopril therapy on sodium and water excretion in patients with liver cirrhosis and ascites].

Authors:  R Brunkhorst; E Wrenger; K Kühn; F W Schmidt; K Koch
Journal:  Klin Wochenschr       Date:  1989-08-01

9.  Effect of captopril on renin and blood pressure in cirrhosis.

Authors:  B Stanek; F Renner; A Sedlmayer; K Silberbauer
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

10.  Sodium handling in patients with well compensated cirrhosis is dependent on the severity of liver disease and portal pressure.

Authors:  R Jalan; P C Hayes
Journal:  Gut       Date:  2000-04       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.